FDA Approves von Willebrand Factor (Recombinant) as Prophylaxis for Adults with Severe Type 3 Disease
Summary : In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5…
Summary : In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5…